Intensity Therapeutics Inc 已正式向瑞士药品监督管理局（Swissmedic）及瑞士伦理委员会提交临床试验方案修订申请，旨在恢复其代号为“Invincible-4”的研究项目患者入组工作。此次提交的修订内容涉及对研究方案的调整，公司期待在获得监管批准后，尽快重新启动受试者招募。
Intensity Therapeutics Inc 已正式向瑞士药品监督管理局（Swissmedic）及瑞士伦理委员会提交临床试验方案修订申请，旨在恢复其代号为“Invincible-4”的研究项目患者入组工作。此次提交的修订内容涉及对研究方案的调整，公司期待在获得监管批准后，尽快重新启动受试者招募。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.